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1106rug-eluting stents (DES) have been shown to be safe
nd more effective than bare-metal stents (BMS) in
educing the need for target vessel revascularization
TVR) in patients with noncomplex lesions undergoing
lective percutaneous coronary intervention (PCI) (1,2).
See page 1113
he safety and efficacy of DES for off-label use in patients
ndergoing PCI for lesions in saphenous vein grafts (SVG)
emains controversial. There have been 2 small randomized
rials (3–5) and several small registries (6–17) comparing
ES with BMS in patients undergoing SVG PCI, but
hese studies have been limited by small numbers of patients
ith short-term follow-up and have had conflicting results.
The STENT (Strategic Transcatheter Evaluation of New
herapies) registry is a multicenter prospective registry
esigned to evaluate late outcomes with DES in the U.S.
his study was designed to test the hypothesis that the use
of DES compared with BMS
with SVG intervention is safe
and effective in reducing TVR.
Methods
The STENT group. The STENT
Group created a multicenter
registry to evaluate coronary ar-
tery stent use and outcomes in
real-world clinical settings in the
U.S. beginning in May 2003.
Patients undergoing PCI were
consented at 8 coronary inter-
ventional centers for participa-
tion including 9-month and
-year follow-up. The STENT registry is supported by
nrestricted grants from industry. Detailed methodology of
his registry has been previously reported (18,19).
eﬁnitions. Re-infarction was defined as a clinical event
ith new elevation of creatine kinase (CK) and elevation of
he myocardial band fraction of CK 2 times normal and
ncludes both ST-segment elevation and non–ST-segment
levation myocardial infarction (MI). Target vessel revascu-
arization (TVR) was defined as a repeat procedure any-
here in the target vessel, including repeat PCI or coronary
rtery bypass graft surgery. Target vessel revascularization
as used instead of target lesion revascularization (TLR),
ecause determinations were assessed by the operators
ithout a core angiographic laboratory to distinguish TLR
rom TVR occurring at sites other than the target lesion.
tent thrombosis was defined with a modified Academic
esearch Consortium definition of definite or probable
bbreviations and
cronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
CI  percutaneous
oronary intervention
VG  saphenous vein graft
IMI  Thrombolysis In
yocardial Infarction
LR  target lesion
evascularization
VR  target vessel
evascularizationtent thrombosis: angiographically documented stent phrombosis, a MI in the distribution of the target vessel, or
udden cardiac death.
tudy population. Our study population is shown in Figure
. Of 26,941 PCI procedures performed at 8 centers from
ay 2003 through June 2006, 24,384 were consented to
articipate in the STENT Registry (90.5%), 20,905 patients
ad unique procedures (first procedure in the registry), and
,380 had SVG intervention. Of these, 348 received BMS
nly and 820 received DES only. Follow-up for the registry
oncluded June 2007. Follow-up at 9 months was obtained
n 343 of the BMS patients (98.6%) and 785 of the DES
atients (95.7%). Follow-up at 2 years was obtained in 252
f the BMS patients (98.1% of those eligible) and 407 of the
ES patients (94.9% of those eligible).
Of the 785 patients treated with DES, 59% were treated
ith sirolimus-eluting stents, 38% were treated with
aclitaxel-eluting stents, and 3% received both stents.
ata collection. All data were collected prospectively by study
oordinators at participating hospitals. Procedural data, includ-
ng adjunctive pharmacology, device use, reference vessel di-
meter, lesion length, and lesion characteristics were assessed
y the operating interventional cardiologist. Post-discharge
linical follow-up was conducted by telephone interview at 9
nd 24 months after the procedure. Complete hospital records
ere reviewed for every patient reporting a cardiac event after
he index hospital stay. All data were entered into a centralized
eb-based database for quality control and statistical analysis
R. Stuart Dickson Institute for Health Studies, Charlotte,
orth Carolina). Physician investigators adjudicated all major
vents, including death, TVR, and stent thrombosis, and site
udits were performed on 10% of the first 4,000 procedures
nd 5% thereafter.
tatistical methods. Baseline and outcome variables were
ompared with t tests for continuous variables and the
hi-square test or Fisher exact test for categorical variables.
p value 0.05 was considered statistically significant. All
nalyses were performed with SAS version 9.1 (SAS Insti-
ute, Inc., Cary, North Carolina).
Kaplan-Meier event curves were constructed for out-
ome variables, and comparisons were made between
ES and BMS with log-rank tests. To adjust for
ifferences in baseline risk profile between patients
reated with DES and those treated with BMS, propen-
ity scores were calculated with a logistical regression
odel (20). All relevant baseline clinical and angio-
raphic variables were included in the model. Propensity
cores were then entered into the individual Cox propor-
ional hazard regression models. These models were used
o provide adjusted comparisons of event rates between
ES and BMS for the outcome variables. Multivariable
ox regression analysis was used to evaluate potential
redictors of TVR.
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1107esults
aseline clinical and angiographic variables. Patients treated
ith DES had a higher incidence of hypertension and
Total P
n = 
Procedure
n = 
90
Unique
(First Proced
n = 
SV
n =
DES ONLY 
n = 820
DES ONLY 
Completed 
9-mo f/u 
n = 785 
(95.7%)
Enrollment 
May 2003 to June 2006 
DES Only 
Completed 
2 year f/u 
n = 407 
(94.9% of eligible patients) 
Figure 1. Our Study Population Consisting of All Patients With SVG Interve
9-Month or 2-Year Follow-Up
BMS  bare-metal stent(s); DES  drug-eluting stent(s); f/u  follow-up; PCI 
Table 1. Baseline Clinical Variables
Age, yrs
Male
Diabetes (any)
Hypertension
Hyperlipidemia
Smoker (ever)
Prior infarction
Prior percutaneous coronary intervention
ST-segment elevation myocardial infarction
Cardiogenic shock
Acute congestive heart failure
Values are mean SD or n (%).BMS bare-metal stent(s); DES drug-eluting stent(s).yperlipidemia but a lower incidence of ST-segment eleva-
ion MI and emergent procedures (Tables 1 and 2). The
ES patients had smaller vessel size and longer lesion
ength (Table 2).
ures 
1 
sented 
4 
ents 
 Registry)
5 
I 
BMS ONLY 
n = 348 
BMS ONLY 
Completed 
9-mo f/u 
n = 343 
(98.6%)
BMS Only 
Completed 
2 year f/u 
n = 252 
(98.1% of eligible patients) 
Who Were Treated With DES Only or BMS Only and Who Completed
utaneous coronary intervention; SVG  saphenous vein graft.
S
343)
DES
(n  785) p Value
10.2 67.5 10.3 0.1
9.6) 604 (77.6) 0.48
7.3) 299 (38.1) 0.75
9.9) 669 (85.2) 0.03
8.0) 513 (65.4) 0.02
7.7) 474 (60.4) 0.43
2.3) 339 (43.2) 0.79
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1108rocedural and in-hospital outcomes. Patients treated with
ES had less no-reflow, a higher incidence of final TIMI
ow grade 3, and a higher angiographic success rate (Table 2).
here were no significant differences between DES and
MS in in-hospital death (0.8% vs. 1.5%, p  0.33) or
n-hospital MI (2.0% vs. 4.1%, p  0.16).
ropensity score adjustment. All significant univariate pre-
ictors of stent type as well as other clinically relevant
ariables were used in the propensity score model. The
odel had good fit (C  0.825), and the model character-
stics are shown in the Online Table A. All predictor
ariables in the propensity score model were shown to
ecome nonsignificant after adjustment (Online Table B).
ate outcomes. Patients treated with DES compared with
MS had a significantly lower frequency of death at 2 years
y unadjusted and adjusted analyses (Table 3) and had a
ignificantly lower frequency of death or MI at 9 months
nd 2 years by unadjusted analyses and at 9 months by
djusted analyses (Table 3, Fig. 2). The event curves for
eath or MI diverged early with most of the differences
Table 2. Angiographic and Procedural Variables
Patient-level analysis
Procedural indication
Elective
Urgent
Emergent
Ejection fraction, %
Multivessel coronary artery disease
Multivessel percutaneous coronary intervention
Multilesion percutaneous coronary intervention
Multiple stents/procedure
Intra-aortic balloon pump
Adjunctive pharmacology
Any GP IIb/IIIa inhibitor
Bivalirudin
Enoxaparin
Lesion-level analysis
Reference vessel diameter, mm
Reference vessel diameter 3.5 mm
Reference vessel diameter 4.5 mm
Lesion length, mm
Lesion length 28 mm
Stent length/lesion
Ostial lesion
Distal protection device used
TIMI ﬂow grade 2–3 pre-PCI
TIMI ﬂow grade 3 post-PCI
No reﬂow (transient or ﬁnal TIMI ﬂow grade 0–1)
Angiographic success*
Values are mean SD or n (%). *Angiographic success:50% residua
GP glycoprotein; PCI percutaneous coronary intervention; otheccurring in the first few weeks (Fig. 2). (The TVR was lower with DES at 9 months, but by 2
ears the event curves crossed, and TVR was slightly higher
ith DES than with BMS (Table 3, Fig. 3). After adjust-
ents with propensity analyses, the event curves for TVR
ere significantly lower with DES compared with BMS
oth at 9 months and 2 years (Table 3, Fig. 3). When only
atients who completed 2-year follow-up were analyzed,
here were no significant differences in the frequency of
VR between DES and BMS by unadjusted analyses
19.0% vs. 16.5%, log rank p  0.67) or propensity adjusted
ox regression (hazard ratio [HR]: 0.78, 95% confidence
nterval [CI]: 0.48 to 1.25, p  0.30).
There were significantly fewer major adverse cardiac
vents (death, MI, or TVR) with DES compared with BMS
t 9 months and 2 years by adjusted analyses (Table 3).
Stent thrombosis was lower with DES than BMS at 9
onths by adjusted analyses, but by 2 years the event
urves crossed, and there were no significant differences
etween the 2 groups (Table 3, Fig. 4). The incidence of
tent thrombosis between 9 months and 2 years was 2.0%
BMS DES p Value
(n  343) (n  785)
96 (28.1) 258 (32.9) 0.005
207 (60.5) 480 (61.2)
39 (11.4) 47 (6.0)
6.1 14.2 46.2 13.3 0.11
246 (74.8) 541 (78.9) 0.15
28 (8.2) 91 (11.6) 0.09
83 (24.2) 220 (28.0) 0.18
127 (37.0) 328 (41.8) 0.17
4 (1.2) 5 (0.6) 0.47
165 (48.1) 365 (46.5) 0.65
61 (17.8) 329 (41.9) 0.001
36 (10.5) 56 (7.1) 0.06
(n  451) (n  1,047)
3.7 0.8 3.3 0.5 0.001
116 (25.8) 433 (41.7) 0.001
105 (23.4) 41 (4.0) 0.001
6.4 10.2 18.2 13.2 0.003
43 (9.6) 136 (13.1) 0.057
2.0 12.2 25.0 15.4 0.001
45 (10.0) 108 (10.3) 0.17
152 (33.7) 391 (37.3) 0.27
397 (88.2) 955 (91.8) 0.003
421 (93.6) 1,027 (98.2) 0.001
31 (6.9) 34 (3.3) 0.002
440 (97.6) 1,040 (99.3) 0.008
is with Thrombolysis In Myocardial Infarction (TIMI) flow grade2.
viations as in Table 1.4
1
2
l stenos8 of 407) with DES and 0.4% (1 of 252) with BMS (log
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1109ank p  0.11 by landmark analysis). The analysis of
tent thrombosis events with Cox regression modeling
hould be interpreted with caution, because the event
ates were low.
redictors of TVR. Independent predictors of TVR at 9
onths by Cox regression analysis included BMS use (HR:
.61, 95% CI: 1.04 to 2.50, p  0.03) and SVG reference
iameter 3.5 mm (HR: 1.74, 95% CI: 1.13 to 2.67, p 
.01). Diabetes and long lesion length (28 mm) were not
ignificant predictors of TVR. In patients with 2-year follow-
p, stent type and SVG reference diameter3.5 mm were no
onger significant independent predictors of TVR.
Table 3. Outcomes
BMS
(n  343) (%)
DES
(n  785
Outcomes at 9 months
Death 7.1 4.6
Myocardial infarction 8.4 5.4
Death/myocardial infarction 14.1 8.7
Target vessel revascularization 10.0 7.2
Stent thrombosis 2.1 1.2
MACE 21.4 13.9
Outcomes at 2 yrs
Death 14.7 8.2
Myocardial infarction 11.3 11.9
Death/myocardial infarction 22.3 17.0
Target vessel revascularization 16.9 18.3
Stent thrombosis 2.5 3.2
MACE 33.8 30.4
Events are expressed as Kaplan-Meier estimates. Hazard ratios are obtained with propensity adjuste
CI confidence interval; MACEmajor adverse cardiac events (death, myocardial infarction or
Figure 2. Kaplan-Meier Estimates of Event Rates for Death or MI in
Patients Undergoing SVG Intervention With DES Versus BMS
HR  hazard ratio; MI  myocardial infarction; other abbreviations as in
Figure 1.Subgroup analysis in patients with 9-month follow-up
howed that TVR was less with DES than with BMS in
atients with SVG reference diameter 3.5 mm (8.0% vs.
7.2%, p  0.013) but not in patients with SVG reference
iameter 3.5 mm (6.0% vs. 6.6%, p  0.74). The TVR at
months was not significantly different between DES and
MS in diabetic patients and in patients with long lesions
28 mm).
iscussion
he “off-label” use of DES for treatment of SVG lesions has
een a subject of great interest and controversy, with no
Log Rank
p Value
Adjusted Hazard Ratio
(95% CI)
Adjusted
p Value
0.097 0.54 (0.28–1.01) 0.055
0.062 0.56 (0.31–1.01) 0.054
0.006 0.52 (0.33–0.83) 0.006
0.11 0.36 (0.22–0.61) 0.001
0.24 0.22 (0.07–0.69) 0.009
0.001 0.45 (0.31–0.65) 0.001
0.005 0.60 (0.36–0.98) 0.041
0.74 0.95 (0.58–1.56) 0.83
0.023 0.74 (0.51–1.08) 0.12
0.86 0.60 (0.40–0.90) 0.014
0.99 0.45 (0.17–1.17) 0.10
0.063 0.68 (0.51–0.92) 0.011
egression.
essel revascularization); other abbreviations as in Table 1.
Figure 3. Kaplan-Meier Estimates of Event Rates for TVR in Patients
Undergoing SVG Intervention With DES Versus BMS
TVR  target vessel revascularization; other abbreviations as in Figures 1) (%)
d Cox rand 2.
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1110eneral consensus regarding whether DES have an advan-
age over BMS in this patient population. There have been
small randomized trials comparing DES with BMS in
VG intervention, with conflicting results. Brilakis et al. (3)
eported the results from the SOS (Stenting Of Saphenous
ein Grafts) trial and found less restenosis and less TLR in
9 patients treated with paclitaxel-eluting stents compared
ith 41 patients treated with BMS at 1 year. The RRISC
Reduction in Restenosis in Saphenous vein grafts with
ypher Stent) trial found less TVR with 38 patients treated
ith sirolimus-eluting stents compared with 37 patients
reated with BMS at 6 months, but this benefit was lost at
years, and mortality was higher with DES at 2 years (4,5).
There have been a number of small registries comparing
ES with BMS in SVG intervention, also with conflicting
esults. Most (6,7,9,10,15) but not all (8,13) registries with
hort-term follow-up have shown less TVR with DES at 6
o 12 months. However, registries with longer follow-up
ave shown less consistent benefit. Two registries found less
VR with DES at 2 to 3 years (14,16), but 3 other registries
ound no difference in TVR at 2 to 2.5 years (11,12,17). An
dditional registry showed less TVR with DES at 1 year,
ut this benefit was lost by 2 years (11). Most registries have
hown no differences in the frequency of death or MI
etween DES and BMS with follow-up from 6 to 30
onths (6–8,11–14,17). One registry showed less death or
I with DES at 9 months (6).
Our prospective registry includes 785 patients undergoing
VG intervention who were treated with DES. The largest
reviously reported SVG registry included only 141 patients
reated with DES (16). We found that DES, compared
ith BMS, reduced TVR at 9 months, but this advantage
Figure 4. Kaplan-Meier Estimates of Event Rates for Stent Thrombosis in
Patients Undergoing SVG Intervention With DES Versus BMS
Abbreviations as in Figures 1 and 2.ecreased over time such that at 2 years TVR rates were wlightly higher with DES versus BMS (Fig. 2). Adjusted
omparisons of TVR for DES versus BMS over 2 years still
avored DES, and there are likely 2 explanations for this.
irst, DES were used in lesions at higher risk for TVR
smaller vessels, longer lesions); so after adjusting for these
ifferences, comparisons might favor DES. Secondly, com-
arison of TVR event curves for DES versus BMS might
rimarily reflect the differences in the curves in the early
onths. When only patients with 2-year follow-up were
valuated with adjusted analyses, there was no significant
enefit of DES over BMS in reducing TVR.
The early benefit of reduced TVR with DES was most
ronounced in patients with SVG reference diameter 3.5
m, with little apparent benefit in patients with SVG
eference diameter 3.5 mm. The DES did not seem to
ave any preferential advantage over BMS in patients with
ong versus short lesions and in patients with and without
iabetes. None of the prior registries were large enough to
llow subgroup analyses, but 1 small study found a lower
requency of TVR with DES for ostial SVG lesions (14).
The late “catch-up” phenomenon in TVR seen in our
tudy (and 2 previous studies) (5,11) whereby TVR is
educed with DES at 9 months but not at 2 years might be
elated to unique features of SVGs and SVG intervention
21). Once disease develops in SVGs, progression of disease
s much more rapid than in native vessels (22,23). Target
esion revascularization after SVG intervention occurs more
ommonly at untreated sites other than at the target lesion
fter the first year (22), and this might dilute the benefit of
ES in reducing TVR at the lesion site (24). This progres-
ion of disease at SVG sites other than the target lesion
ight account for most of the TVR from 9 months to 2
ears and might explain why the TVR event curves for DES
nd BMS merge over time. Our data do not allow us to
valuate this possibility, because we are not able to distin-
uish between TLR and TVR. However, data from the
ELAYED RRISC (Death and Events at Long-term
ollow-up AnalYsis: Extended Duration of the Reduction of
estenosis In Saphenous vein grafts with Cypher stent) trial
uggest that TVR at sites other than the target lesion might
ontribute to this “catch-up” phenomenon (5).
A second possible explanation for the late “catch-up” in
VR with DES is that angiographic late loss and restenosis
fter the first 9 months might be more common with DES
han with BMS after SVG intervention. Angiographic late
oss after BMS implantation in native coronary arteries
enerally peaks at 6 to 9 months, after which there might be
ome regression (25). Consequently, restenosis and TVR
re uncommon with BMS after 6 to 9 months. Conversely,
ngiographic late loss might continue with DES after 9
onths, and this might be associated with late restenosis
nd TLR (26). Although the frequency of late restenosis
ith DES in native vessels is relatively small, the frequency
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1111f late restenosis after SVG intervention with DES could be
reater (27).
Our data suggest that DES are safe with SVG interven-
ion. Death or MI was less frequent with DES, and there
ere no differences in the frequency of stent thrombosis
etween DES and BMS. Although propensity analysis was
sed to adjust for differences in baseline variables between
ES and BMS, the differences in death or MI might be due
o hidden selection biases that cannot be accounted for with
ropensity adjustments. The fact that most of the differ-
nces in death or MI between DES and BMS in our registry
ccurred in the first 30 to 60 days before the benefits of
ES in reducing TVR are evident (Fig. 2) suggests that
hese differences might be due to selection biases.
tudy limitations. Although our study provides an opportu-
ity to compare “real world” outcomes with DES versus
MS in patients undergoing SVG intervention, it has the
imitations of an observational database. As mentioned
arlier, there might be hidden biases to choose BMS for
icker patients who might have multiple comorbidities or
leeding risks or who might be noncompliant with dual
ntiplatelet therapy as well as other therapies. These biases
ight not be accounted for by statistical adjustments. Thus,
ur data could overestimate the safety of DES compared
ith BMS with regard to death or MI and stent thrombosis.
onversely, there could be hidden biases in selecting pa-
ients for DES who have a higher chance of developing the
eed for TVR. These biases might not be accounted for by
djustments for variables known to affect TVR, such as
iabetes, vessel size, and lesion length. Thus, our data could
nderestimate the benefits of DES in reducing TVR.
The SVG reference diameter, lesion length, and TIMI
ow were assessed by the operators rather than by core
aboratory analysis. Also, without core laboratory angio-
raphic analysis, we are not able to distinguish between
LR and TVR. This limits our ability to evaluate the
echanisms accounting for differences in TVR between
ES and BMS. We also do not have data regarding SVG
ge and the extent of degeneration that might impact TVR.
Our registry does not have data regarding compliance
ith dual antiplatelet therapy. This is an important limita-
ion, because compliance with clopidogrel and aspirin is a
ajor determinant of stent thrombosis and adverse events
28,29). We also do not have data regarding compliance
ith other adjunctive medical therapies and risk factor
odification that might impact outcomes.
linical implications. Our data indicate that the use of DES
ompared with BMS in SVG intervention is effective in
educing TVR in the short term, but most of this benefit
eems to have been lost by 2 years. The short-term benefit
eems to be most pronounced in SVGs with small reference
umen diameter (3.5 mm), and there seems to be little
enefit in SVGs with large reference lumen diameter.Our data indicate that SVG intervention with DES
ompared with BMS is safe out to 2 years, with lower rates
f death or MI and similar rates of stent thrombosis.
lthough these differences might be due to unmeasured
iases to select BMS for sicker patients, the data are
eassuring in that there do not seem to be any safety
oncerns with the use of DES with SVG intervention.
It seems reasonable, on the basis of these data, to use
ES with SVG intervention in grafts with reference diam-
ter 3.5 mm for short-term benefit, realizing that the
enefit might be attenuated at long-term follow-up. Large
andomized trials powered for clinical outcomes would be
equired to determine whether this short-term benefit with
ES will be worth the additional cost.
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